[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhang XIao Mei\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100552009","phase-4-to-investigate-the-effect-of-esketamine-hydrochloride-on-pulmonary-complications-100552009",false,"NCT06467513","To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications","To Investigate the Effect of Esketamine on Hemodynamics and Postoperative Pulmonary Complications in Patients Undergoing Heart Valve Replacement Surgery","Inclusion Criteria:\n\n* Age 18-75 years old, gender unlimited.\n* Elective heart surgery.\n* Patients who plan to undergo mitral and (or) aortic valve replacement (or repair) surgery, requiring extracorporeal circulation and aortic occlusion.\n* The New York Heart Association class is less than 4.\n* Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Non-cardiac surgery.\n* Second heart surgery.\n* Interventional surgery in heart valve surgery (TAVI, mitral clamp).\n* The patient refuses.\n* Pregnant women.\n* Patients with a history of lung surgery.\n* Patients with acute kidney injury requiring dialysis.\n* Patients with chronic renal insufficiency (stage III and above).\n* The patient was intubated before arriving at the operating room.\n* Patients with existing pulmonary complications (respiratory tract infection, pneumonia, pleural effusion, respiratory failure, atelectasis, pneumothorax, bronchospasm, ARDS).\n* The patient had neuropsychiatric disease and cognitive impairment before surgery.\n* Drug users and other long-term use of antipsychotic drugs.\n* Patients with any of the following contraindications for the use of ESketamine injection: patients with serious risk of elevated blood pressure or intracranial pressure; Patients with high intraocular pressure (glaucoma) or penetrating ocular trauma; Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic pressure exceeding 180 mmHg, or resting diastolic pressure exceeding 100mmHg); Patients with untreated or undertreated hyperthyroidism (hyperthyroidism).\n* Liver function ALT, AST \\> 2 times normal.","ALL","18 Years","75 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The objective of this study was to evaluate the effect of esketamine on intraoperative hemodynamics in patients with heart valve replacement and to mitigate postoperative pulmonary complications",[27,28],"Heart Diseases","Heart Valve Diseases","RECRUITING","2024-06-14",{"date":32,"type":33},"2024-06-21","ACTUAL",{"date":35,"type":33},"2024-01-01",{"date":37,"type":21},"2025-05",{"name":39,"class":40},"Zhang XIao Mei","OTHER",""]